ReviewEuropean respiratory review : an official journal of the European Respiratory Society2013
Immunosuppression for interstitial lung disease in systemic sclerosis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox.Biomedicines · 2022Article
- A new nucleosomic-based model to identify and diagnose SSc-ILD.Clinical epigenetics · 2020Article
- Identification and Validation of Key Genes Associated With Systemic Sclerosis-Related Pulmonary Hypertension.Frontiers in genetics · 2020Article
- The effectiveness of immunosuppressive cyclosporin in attenuating the progression of interstitial lung diseases.Journal of thoracic disease · 2019Article
- Long-term effects of immunosuppressive therapy on lung function in scleroderma patients.Clinical rheumatology · 2018Article
- Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management.Reumatologia · 2018Review
- Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.Annals of the American Thoracic Society · 2016Review
- Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?Clinical rheumatology · 2015Article
- Cellular interactions in the pathogenesis of interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- Scleroderma-related lung disease: are adipokines involved pathogenically?Current rheumatology reports · 2013Review
- Future perspectives on rare pulmonary diseases and rare presentations of common disorders.European respiratory review : an official journal of the European Respiratory Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of immunosuppressors in the treatment of systemic sclerosis-interstitial lung disease is still matter of controversy. In this review we will analyse the evidence that immunosuppressors, despite not being able to reverse fibrotic changes, may help in slowing disease progression. Induction treatment with cyclophosphamide should be started as soon as possible in patients at risk for progression. Mycophenolate mofetil and rituximab have to be considered in patients who are unable to tolerate cyclophosphamide. After remission, maintenance treatment with mycophenolate mofetil or azathioprine should be started in order to preserve the benefits achieved during the induction treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.